Population Immunity against Serotype-2 Poliomyelitis Leading up to the Global Withdrawal of the Oral Poliovirus Vaccine: Spatio-temporal Modelling of Surveillance Data

English version České info

Isobel Mary Blake and colleagues use spatio-temporal modelling of surveillance data to estimate population immunity leading up to the global withdrawal of serotype-2 oral poliovirus vaccine.

Vyšlo v časopise: Population Immunity against Serotype-2 Poliomyelitis Leading up to the Global Withdrawal of the Oral Poliovirus Vaccine: Spatio-temporal Modelling of Surveillance Data. PLoS Med 13(10): e32767. doi:10.1371/journal.pmed.1002140
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002140

Souhrn

Isobel Mary Blake and colleagues use spatio-temporal modelling of surveillance data to estimate population immunity leading up to the global withdrawal of serotype-2 oral poliovirus vaccine.

Zdroje

1. World Health Organization. The polio eradication & endgame strategic plan 2013–2018. Geneva: World Health Organization; 2013.

2. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587–635. 16153180

3. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004;292:1696–1701. 15479934

4. Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M, Corander J, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med. 2010;362:2360–2369. doi: 10.1056/NEJMoa0910074 20573924

5. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, July 2009–March 2011. MMWR Morb Mortal Wkly Rep. 2011;60:846–850. 21716199

6. Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014;210(Suppl 1):S283–S293. doi: 10.1093/infdis/jiu295 25316847

7. Global Polio Eradication Initiative. Classification and reporting of vaccine-derived polioviruses (VDPV). 2015 Aug [cited 2 Sep 2016]. Available: http://www.polioeradication.org/Portals/0/Document/Resources/VDPV_ReportingClassification.pdf.

8. Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus. 2015 [cited 2 Nov 2015]. Available: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx.

9. Centers for Disease Control and Prevention. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep. 2001;50:222–224. 11300627

10. Global Commission for the Certification of Poliomyelitis Eradication. Eradicating polio. Science. 2015;350:609. doi: 10.1126/science.aad7294 26542542

11. Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8:e1002599. doi: 10.1371/journal.ppat.1002599 22532797

12. Global Polio Eradication Initiative. The switch from tOPV to bOPV: implementation guidelines. 2015 Aug [cited 2 Sep 2016]. Available: http://www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/oral_polio_vaccine/OPV-Switch-Guidelines-Aug2015.pdf?ua=1.

13. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012—conclusions and recommendations. Wkly Epidemiol Rec. 2013;88:1–16. 23311010

14. El-Sayed N, El-Gamal Y, Abbassy AA, Seoud I, Salama M, Kandeel A, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med. 2008;359:1655–1665. doi: 10.1056/NEJMoa0800390 18923170

15. Grassly NC, Wenger J, Durrani S, Bahl S, Deshpande JM, Sutter RW, et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet. 2007;369:1356–1362. 17448821

16. Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010;376:1682–1688. doi: 10.1016/S0140-6736(10)61230-5 20980048

17. Waggie Z, Geldenhuys H, Sutter RW, Jacks M, Mulenga H, Mahomed H, et al. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa. J Infect Dis. 2012;205:228–236. doi: 10.1093/infdis/jir721 22158680

18. World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, October 2015—conclusions and recommendations. Wkly Epidemiol Rec. 2015;90:681–699. 26685390

19. Levitt A, Diop OM, Tangermann RH, Paladin F, Kamgang JB, Burns CC, et al. Surveillance systems to track progress toward global polio eradication—worldwide, 2012–2013. MMWR Morb Mortal Wkly Rep. 2014;63:356–361. 24759658

20. Grassly NC, Fraser C, Wenger J, Deshpande JM, Sutter RW, Heymann DL, et al. New strategies for the elimination of polio from India. Science. 2006;314:1150–1153. 17110580

21. Mangal TD, Aylward RB, Mwanza M, Gasasira A, Abanida E, Pate MA, et al. Key issues in the persistence of poliomyelitis in Nigeria: a case-control study. Lancet Glob Health. 2014;2:e90–e97. doi: 10.1016/S2214-109X(13)70168-2 25104665

22. Pons-Salort M, Burns CC, Lyons H, Blake IM, Jafari H, Oberste MS, et al. Preventing vaccine-derived poliovirus emergence during the polio endgame. PLoS Pathog. 2016;12:e1005728. doi: 10.1371/journal.ppat.1005728 27384947

23. Project R-INLA. R-INLA package. Version 0.0–1466099681. 2016 [cited 2 Sep 2016]. Available: http://www.r-inla.org.

24. Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis. 2014;210(Suppl 1):S439–S446. doi: 10.1093/infdis/jit601 24634499

25. O’Reilly KM, Cori A, Durry E, Wadood MZ, Bosan A, Aylward RB, et al. A new method to estimate the coverage of mass vaccination campaigns against poliomyelitis from surveillance data. Am J Epidemiol. 2015;182:961–970. doi: 10.1093/aje/kwv199 26568569

26. Carnell R. lhs: latin hypercube samples. Version 0.14. 2016 Aug 9 [cited 2 Sep 2016]. Available: https://CRAN.R-project.org/package=lhs.

27. R Project for Statistical Computing. R: a language and environment for statistical computing. Version 3.2.3. 2015 Dec 10 [cited 2 Sep 2016]. Available: http://www.R-project.org/.

28. Farag NH, Wadood MZ, Safdar RM, Ahmed N, Hamdi S, Tangermann RH, et al. Progress toward poliomyelitis eradication–Pakistan, January 2014–September 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1271–1275. doi: 10.15585/mmwr.mm6445a4 26584026

29. World Health Organization. Nigeria: WHO and UNICEF estimates of immunization coverage: 2015 revision. 2016 Jul 5 [cited 2 Sep 2016]. Available: http://who.int/immunization/monitoring_surveillance/data/nga.pdf.

30. Grassly NC, Jafari H, Bahl S, Sethi R, Deshpande JM, Wolff C, et al. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. J Infect Dis. 2012;205:1554–1561. doi: 10.1093/infdis/jis241 22448007

31. Asghar H, Diop OM, Weldegebriel G, Malik F, Shetty S, El Bassioni L, et al. Environmental surveillance for polioviruses in the Global Polio Eradication Initiative. J Infect Dis. 2014;210(Suppl 1):S294–S303. doi: 10.1093/infdis/jiu384 25316848

32. Global Polio Eradication Initiative. Operational framework for monovalent oral poliovirus type 2 (mOPV2) deployment and replenishment (during the endgame period). 2015 Jan 9 [cited 2 Sep 2016]. Available: http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/mOPV2_Operational_Framework.pdf.